Intravesical Gemcitabine (Inlexzo) for Bladder Cancer

The FDA has approved Inlexzo, a gemcitabine intravesical system, for treatment of Bacillus Calmette- Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-10-09
DOI: https://doi.org/10.58347/tml.2025.1740c
Primary Topic: Bladder and Urothelial Cancer Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Intravesical Gemcitabine (Inlexzo) for Bladder Cancer

Oct 9, 2025

The medical letter on drugs and therapeutics/The medical letter

Bladder and Urothelial Cancer Treatments

article

Intravesical Gemcitabine (Inlexzo) for Bladder Cancer

October 9, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1740)

Openalex Percentile: Top 55%

Bladder and Urothelial Cancer Treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Intravesical Gemcitabine (Inlexzo) for Bladder Cancer · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS